SCODiA Report by MLBI Lab

Single-Cell Analysis of Lung Cancer: Dissecting Cellular Heterogeneity, Genomic Instability, Immune Microenvironment Remodeling, and Intercellular Communication Across Disease Stages

This single-cell RNA-sequencing analysis of human lung tissue reveals significant cellular heterogeneity and dynamic changes across normal, early, and advanced lung cancer stages. Aneuploid Lung Epithelial cells, identified as the tumor origin, exhibit extensive genomic instability with recurrent oncogenic amplifications, and drive proliferative and metabolic reprogramming. The tumor microenvironment undergoes substantial remodeling, characterized by the expansion of malignant epithelial cells, depletion of NK cells, enrichment of regulatory T cells and pro-tumorigenic M2-like macrophages, and a shift in cell-cell communication towards pro-growth and immunosuppressive signaling. These findings highlight key molecular and cellular drivers of lung cancer progression and offer potential diagnostic and therapeutic avenues.

Contents

  1. Dataset overview
  2. UMAP Visualization of Cell Conditions, Samples, Cell Types, and Ploidy in Lung scRNA-seq Data
  3. Major Cell Type Score and Ploidy Distribution on UMAP
  4. Marker Expression Dot Plot for Lung Single-Cell Subsets
  5. Analysis of Copy Number Variations in Tumor-Origin Lung Epithelial Cells
  6. UMAP Visualization of CNV Patterns by Cell Type, Ploidy, Condition, and Sample
  7. Minor Cell Type Population Analysis Across Lung Conditions
  8. T cell Subtype Population Dynamics Across Lung Cancer Progression
  9. Immune Cell Population Shifts in Lung Cancer Progression
  10. Macrophage Subset Population Dynamics in Lung Cancer Progression
  11. Macrophage Subset Population Dynamics in Lung Cancer Progression
  12. Ploidy Analysis of Tumor-Origin Lung Epithelial Cells Across Disease Stages
  13. Cell-Cell Interaction Patterns Across Lung Cancer Progression
  14. Cell-Cell Interaction Analysis of Immune Checkpoint and Cell Cycle Pathways in Lung Cancer Progression
  15. Condition-Specific Cell-Cell Interaction Patterns in Lung Cancer
  16. Lung Epithelial Cell Surfaceome Marker Expression in Lung Cancer
  17. sdk_http_response=HttpResponse(
  18. Fibroblast Condition-Specific Surfaceome Markers in Lung Cancer
  19. CD4+ T Cell Condition-Specific Surface Marker Expression in Lung Cancer
  20. Differential Expression of Cell Cycle Genes in Lung Epithelial Cells Across Tumor Progression
  21. Gene Ontology (GSA) Analysis for Lung Epithelial Cells Across Conditions
  22. Gene Set Enrichment Analysis of Lung Cancer Cell Types
  23. Discussion
  24. Query List

0. Dataset overview

Dataset Summary

1. UMAP Visualization of Cell Conditions, Samples, Cell Types, and Ploidy in Lung scRNA-seq Data

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a series of Uniform Manifold Approximation and Projection (UMAP) plots, visualizing the single-cell RNA-seq dataset based on various metadata annotations: condition (Normal, Tumor(adv), Tumor(early)), individual sample identities, celltype_major, celltype_minor, ploidy_dec (Diploid, Aneuploid, Unclear), and celltype_subset. The UMAP projection helps to assess the overall structure of the dataset, the separation and clustering of different cell populations, and the quality of the annotations. Given the inferred context of Lung Cancer, these visualizations are critical for understanding disease-associated changes in cell populations and the distribution of malignant cells.

Visual Summary

Condition and Sample Distribution

The condition UMAP shows a clear separation between cells from 'Normal' conditions and those from 'Tumor(adv)' and 'Tumor(early)' conditions. The 'Normal' cells (burgundy) largely occupy a distinct region on the left side of the UMAP. 'Tumor(adv)' (yellow) and 'Tumor(early)' (purple) cells extensively overlap but also form distinct sub-clusters, indicating shared cellular states as well as unique aspects associated with disease progression.

The sample UMAP reveals that cells from different samples generally intermix well within the broader condition clusters, suggesting that major batch effects related to individual samples are not dominating the overall UMAP structure. However, some sub-clusters appear to be more enriched for specific samples, which could represent either residual batch effects or unique biological features of those samples.

Cell Type Clustering

The celltype_major UMAP demonstrates distinct clustering for major cell types. T cells (cyan) and Myeloid cells (light green) form large, well-separated clusters. Lung Epithelial cells (orange) appear as multiple interconnected clusters, some of which overlap with both normal and tumor regions. Stromal cells (teal) and Endothelial cells (red-orange) also form relatively distinct clusters. The celltype_minor and celltype_subset UMAPs further resolve these major clusters into more granular populations, showing expected substructures (e.g., T cell CD8+, T cell CD4+, Macrophage subtypes, Alveolar Epithelial cells) that largely cohere as distinct groups.

Ploidy Distribution

The ploidy_dec UMAP shows that Diploid cells (yellow) are widely distributed across the UMAP, encompassing most of the 'Normal' cluster and a substantial portion of the 'Tumor' clusters. Crucially, the 'Aneuploid' cells (burgundy) form distinct clusters that are almost exclusively localized within the regions populated by 'Tumor(adv)' and 'Tumor(early)' cells. This strong spatial segregation of aneuploid cells within tumor regions is a key indicator of their malignant nature. A small number of 'Unclear' cells (purple) are also observed, scattered in minor populations.

Biological Interpretation

  1. Tumor Microenvironment Heterogeneity: The extensive overlap between 'Tumor(adv)' and 'Tumor(early)' cells, combined with the presence of both 'Diploid' and 'Aneuploid' cells within these regions, highlights the significant cellular heterogeneity within the tumor microenvironment (TME) across different stages. This suggests that the TME consists of both malignant (aneuploid) cells and various non-malignant (diploid) stromal and immune cells that are recruited or resident in the tumor.
  2. Malignant Cell Identification: The strong co-localization of 'Aneuploid' cells with tumor conditions (Tumor(adv), Tumor(early)) provides robust evidence for their identification as malignant cells. Given that the 'Resolved tumor-origin cell type' is 'Lung Epithelial cell', it is highly probable that these aneuploid cells largely correspond to the malignant lung epithelial cells driving the tumor growth. The UMAPs for celltype_major, celltype_minor, and celltype_subset should be further inspected to confirm this overlap. For example, specific 'Lung Epithelial cell' clusters that are enriched in aneuploidy and tumor conditions would be strong candidates for the malignant cell populations.
  3. Cell Type Distribution Across Conditions:
    • Immune Cells: T cells and Myeloid cells (e.g., Macrophages) are present across both normal and tumor regions, indicating their dynamic involvement in both healthy tissue maintenance and immune responses within the TME. Differential distribution or distinct states of these immune cells between normal and tumor conditions could point to immune evasion or activation mechanisms.
    • Lung Epithelial Cells: The observed multiple clusters of Lung Epithelial cells (major cell type) and their refined subsets (e.g., Alveolar type 2, Secretory club, Basal cell) are particularly interesting. The subset(s) overlapping with the 'Aneuploid' and 'Tumor' regions likely represent the transformed cancer cells, while others represent normal lung epithelium.
  4. Annotation Quality and Dataset Structure: The clear separation of major and minor cell types into distinct clusters, with minimal mixing, indicates high-quality cell type annotation. The UMAP also effectively captures the biological distinctions between conditions and ploidy states, reinforcing the reliability of the single-cell data and its downstream analyses.

Clinical or Translational Implications

  1. Understanding Tumor Evolution and Heterogeneity: The distinction between 'Tumor(early)' and 'Tumor(adv)' cells, even with overlap, can offer insights into the molecular changes and cellular populations that evolve during lung cancer progression. Identifying unique cell states or enriched cell types in advanced tumors could highlight mechanisms contributing to more aggressive disease.
  2. Identification of Malignant Cells: The precise mapping of aneuploid cells to tumor-specific regions and inferred epithelial cell types is crucial for distinguishing tumor cells from normal cells within a biopsy. This is fundamental for studying tumor-intrinsic biology, identifying oncogenic drivers, and understanding resistance mechanisms.
  3. Immune Landscape in Lung Cancer: The diverse immune cell populations (T cells, Myeloid cells) present in both normal and tumor contexts lay the groundwork for investigating immune cell infiltration, activation states, and their interactions within the TME. This information is vital for developing and monitoring immunotherapies in lung cancer.
  4. Biomarker Discovery: Cell types or states that are uniquely enriched in tumor conditions or exhibit aneuploidy could serve as potential diagnostic or prognostic biomarkers. Further investigation into their specific gene expression profiles would be warranted.

2. Major Cell Type Score and Ploidy Distribution on UMAP

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the distribution of major cell type scores, inferred ploidy status, and final major cell type annotations across a Uniform Manifold Approximation and Projection (UMAP) embedding of single-cell RNA-seq data. The primary goal is to assess the clarity and distinctness of cell type clustering, validate the consistency of cell type assignments based on scores, and observe the spatial relationship between different cell populations and aneuploid cells within the lung tissue context.

Visual Summary

The UMAP plots display the following:

Biological Interpretation

The visualization effectively demonstrates the heterogeneous cellular landscape of the lung tissue.

Annotation Notes

3. Marker Expression Dot Plot for Lung Single-Cell Subsets

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a marker expression dot plot, visualizing the expression patterns of key genes across various celltype_subset populations identified in the single-cell RNA-sequencing data from lung tissue. The primary goal is to assess the quality and distinctness of these cell type annotations by examining the specificity and abundance of known cell-type-specific markers. Each dot represents a gene-cell type pair, with the size of the dot indicating the fraction of cells within that group expressing the gene, and the color intensity representing the mean expression level of the gene in that cell group. Red boxes highlight the primary marker genes used to define or identify each cell subset.

Visual Summary

The dot plot displays a clear diagonal pattern of enriched gene expression, indicating that distinct sets of marker genes are highly and specifically expressed within their corresponding celltype_subset populations. This pattern is robust across most cell types, with large, dark red dots concentrated along the diagonal, confirming high expression and prevalence of these markers within their assigned cell groups. Conversely, these markers show minimal to no expression in other cell types, suggesting strong specificity. The bar charts on the right provide context for the number of cells in each group and the overall mean expression levels, further supporting the observed patterns. The var_group_rotation of 45 degrees for gene labels allows for clear readability of the numerous markers.

Biological Interpretation

The marker expression patterns observed in the dot plot strongly support the distinct identities of the annotated celltype_subset populations.

Lung Epithelial Cells:

These epithelial markers are largely distinct, reinforcing the fine-grained differentiation within lung epithelial lineages.

Immune Cells:

T cell subsets are well-resolved

Stromal and Endothelial Cells:

The patterns indicate a high degree of specificity for most celltype_subset annotations. The marker genes chosen for display effectively discriminate between cell populations, providing confidence in the resolution of the single-cell annotations.

Annotation Notes

The marker expression dot plot serves as a robust validation of the celltype_subset annotations. The observed gene expression patterns are highly consistent with known biological markers for the respective cell types within the lung tissue. The clear specificity of markers, as indicated by strong expression within the assigned cell groups and minimal expression elsewhere, suggests that the cell type assignments are accurate and well-resolved for the majority of the subsets. This level of resolution and confidence in cell identity is crucial for downstream analyses, especially in a complex disease context like Lung Cancer where precise cell typing is essential for understanding disease mechanisms and cellular interactions.

4. Analysis of Copy Number Variations in Tumor-Origin Lung Epithelial Cells

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates copy number variations (CNVs) within Lung Epithelial cells, identified as the tumor-origin cell type. The results are presented as a heatmap displaying log2(Copy Number Ratio) values across the genome for individual samples, grouped by their original cell classification (e.g., LUNG_Nxx, BRONCHO_xx, EBUS_xx, and Diploid LUNG_Txx). A supplementary heatmap summarizes the significantly amplified cytogenetic bands, detailing their presence and magnitude across samples, along with their overall frequency.

Visual Summary

CNV Heatmap (log2(CNR) by Genomic Spot and Sample):

The top heatmap illustrates a distinct pattern of genomic instability in a subset of Lung Epithelial cell samples.

Summary of Significantly Amplified Regions (Cytogenetic Band by Sample):

The bottom heatmap and associated bar chart provide a quantitative summary of the most frequently amplified cytogenetic bands:

Biological Interpretation

The observed CNV patterns strongly support the identification of "Lung Epithelial cells" as the tumor-origin cell type and provide direct evidence for genomic instability characteristic of lung cancer.

Clinical or Translational Implications

The findings have several important clinical implications for lung cancer:

5. UMAP Visualization of CNV Patterns by Cell Type, Ploidy, Condition, and Sample

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents five UMAP (Uniform Manifold Approximation and Projection) plots. These UMAPs visualize the cellular landscape based on inferred copy number variation (CNV) patterns, as indicated by the embed_cfg parameter cnv=True. Each plot colors the cells according to a different metadata annotation: major cell type, minor cell type, ploidy status, disease condition, and individual sample. This allows for an examination of how genomic instability, as captured by CNVs, structures the cellular heterogeneity within the Lung tissue dataset.

Visual Summary

The UMAP embeddings, driven by CNV patterns, reveal distinct clustering that correlates strongly with cellular ploidy, disease status, and specific cell types.

Cell Type Distribution (Major and Minor)

Ploidy Status (ploidy_dec)

Condition (condition)

Sample (sample)

Biological Interpretation

The CNV-driven UMAPs provide compelling insights into the genomic instability landscape of Lung Cancer:

  1. Tumor Cells Exhibit Extensive Aneuploidy and Distinct CNV Patterns: The most striking observation is the clear separation of aneuploid cells from diploid cells in the UMAP, with aneuploid cells forming a highly heterogeneous cluster. This directly aligns with the inferred disease context of Lung Cancer, where genomic instability, including CNVs and aneuploidy, is a hallmark of malignancy. The 'Resolved tumor-origin cell type' being 'Lung Epithelial cell' is strongly supported by the observation that these cells predominantly occupy the aneuploid regions and are associated with tumor conditions. This suggests that the malignant epithelial cells are the primary drivers of the observed aneuploidy.
  2. CNV as a Determinant of Cellular Identity in Tumor Microenvironment: The UMAP embedding, based on CNV patterns, effectively separates cells of normal ploidy (often immune, stromal, and normal epithelial cells from normal samples or tumor microenvironment) from those with significant genomic aberrations (primarily tumor cells). This highlights that CNV profiling can be a powerful tool for distinguishing tumor cells from non-malignant cells, even within the complex tumor microenvironment.
  3. Progression-Associated CNV Heterogeneity: The overlap of 'Tumor(early)' and 'Tumor(adv)' cells within the aneuploid clusters, with advanced tumor cells potentially showing broader dispersion, suggests that while aneuploidy is present early, further genomic evolution and diversification of CNV patterns may occur during tumor progression. This implies that different sub-clones within the tumor might exhibit distinct CNV landscapes.
  4. Cell-Type Specific CNV Signatures: The specific clustering of 'Lung Epithelial cell' (and 'Alveolar Epithelial cell') within the aneuploid regions, distinct from other cell types like T cells or myeloid cells, indicates that the CNV patterns are largely cell-type intrinsic, particularly for the tumor-origin cells. Other cell types (e.g., T cells, B cells, Myeloid cells) primarily reside in the diploid regions, as expected for non-malignant cells in the tumor microenvironment or normal tissue.

Annotation Notes

The consistency between the ploidy_dec UMAP and the condition UMAP, where aneuploid cells largely correspond to tumor conditions and diploid cells to normal conditions, strongly supports the accuracy of the automated ploidy and CNV estimates. Furthermore, the co-localization of 'Lung Epithelial cell' with the aneuploid and tumor clusters reinforces the biological inference of these cells being the tumor-origin cells in Lung Cancer. The use of a CNV-driven embedding successfully captured genomic instability as a primary axis of variation in the dataset.

6. Minor Cell Type Population Analysis Across Lung Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the relative proportions of minor cell types across individual samples from Normal, early-stage Lung Tumor (Tumor(early)), and advanced-stage Lung Tumor (Tumor(adv)) conditions. The goal is to identify shifts in cellular composition associated with lung cancer progression, leveraging single-cell RNA-seq data from human lung tissue. The tumor origin has been resolved as Lung Epithelial cells.

Visual Summary

The visualization reveals distinct differences in minor cell type compositions across the three conditions:

Biological Interpretation

The observed shifts in cell type proportions provide critical insights into the tumor microenvironment (TME) during lung cancer progression:

  1. Malignant Epithelial Cell Expansion: The most striking finding is the significant increase in Alveolar Epithelial cells in tumor samples, progressively becoming more dominant from early to advanced stages. Given that the tumor-origin cell type is identified as "Lung Epithelial cell," this strong enrichment likely represents the proliferation and expansion of malignant tumor cells originating from alveolar epithelial lineage. This is a hallmark of tumor growth and increased tumor burden.
  2. Immune Cell Dynamics and Potential Immunosuppression:
    • T cells: Both CD4+ and CD8+ T cell populations show a relative decrease in tumor samples compared to normal tissue, particularly in advanced tumors. While this could partly be a dilution effect due to the massive expansion of tumor cells, it might also suggest an altered or immunosuppressive TME, where T cell infiltration or retention is impaired, or T cells are functionally exhausted. CD8+ T cells are crucial for anti-tumor immunity, and their reduction can contribute to immune evasion [1].
    • Macrophages: The relative proportion of macrophages also appears reduced in tumor conditions. Macrophages are highly plastic and can adopt pro- or anti-tumoral phenotypes (M1 vs. M2). A decrease in their overall relative proportion in the TME warrants further investigation into their activation state and functional role.
  3. Stromal Remodeling: Fibroblasts and Endothelial cells, key components of the tumor stroma involved in extracellular matrix remodeling and angiogenesis, also show a relative decrease in tumor samples. While their relative proportions are reduced due to tumor cell expansion, their absolute numbers or activation states within the TME could still be functionally critical.

Clinical or Translational Implications

These population shifts have several clinical and translational implications for lung cancer:

---

References

[1] Waldman, A.D., et al. (2020). T-cell-inflamed tumors and the tumor immune microenvironment. *Nat Rev Clin Oncol* 17, 442–458. PubMed Search: T cell inflamed tumor microenvironment lung cancer

[2] Galon, J., et al. (2021). The immune score in cancer. *Immunity* 54, 1892–1904. PubMed Search: tumor immune microenvironment immunotherapy response

7. T cell Subtype Population Dynamics Across Lung Cancer Progression

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the relative proportions of various T cell subsets and related innate lymphoid cells (ILCs) within the 'T cell' major cell type. The data is stratified by individual samples and grouped by clinical condition: 'Normal', 'Tumor(early)', and 'Tumor(adv)'. This visualization allows for a direct comparison of the immune cell landscape within the T cell compartment as lung cancer progresses from normal tissue through early and advanced stages.

Visual Summary

The stacked bar plots display the proportional distribution of 19 different immune cell subtypes, predominantly T cell subsets, for each sample within the three conditions.

Biological Interpretation

The observed population dynamics within the T cell compartment provide insights into the evolving immune landscape during lung cancer progression.

  1. Shift in T cell (Naive) and T cell (Cytotoxic) Proportions: The relative reduction of T cell (Naive) cells in advanced tumors might indicate increased T cell activation and differentiation within the tumor microenvironment (TME), or altered trafficking and retention of these cells. While T cell (Cytotoxic) cells, crucial for anti-tumor immunity, remain a significant population, their *relative* contribution might be outpaced by suppressive elements in advanced disease.
  2. Sustained or Increased Relative Proportion of T cell (Treg): Regulatory T cells (Tregs) are immunosuppressive cells that inhibit effector T cell functions and are often enriched in the TME, contributing to immune evasion. Their consistent presence and potentially increased relative proportion in advanced tumors, especially when compared to a relative decrease in naïve T cells, strongly suggest an active immunosuppressive environment. This can hinder effective anti-tumor responses.
  3. Role of 'unassigned' cells in Tumor(adv): The emergence or increased proportion of 'unassigned' cells in advanced tumors could be biologically significant. These might represent novel or aberrant T cell states within the highly dynamic and often suppressive tumor microenvironment, indicating phenotypic plasticity or exhaustion states that are not captured by the current subset annotations.

Clinical or Translational Implications

The findings highlight potential immune dysregulation in the lung cancer microenvironment, particularly in advanced stages.

8. Immune Cell Population Shifts in Lung Cancer Progression

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents box plots visualizing the proportional representation of key T cell subsets and innate lymphoid cells (ILCs) across different conditions: 'Tumor(early)', 'Normal', and 'Tumor(adv)' (advanced tumor) in the context of Lung tissue. The goal is to identify statistically significant changes in these cell populations during lung cancer development and progression, providing insights into the evolving immune landscape. Pairwise statistical comparisons were performed between conditions to determine significant differences (p < 0.1).

Visual Summary

The box plots illustrate distinct patterns of T cell and ILC subset proportions:

Tfh, Th22, Th17, T_Naive, Treg, Th2 (elevated in early tumor):

NK cells (decreased in tumor conditions):

ILC2 (decreased in advanced tumor):

Biological Interpretation

The observed shifts in immune cell populations reveal a dynamic and complex immune microenvironment throughout lung cancer progression:

  1. Impaired Anti-tumor Immunity:
    • NK cell depletion: The consistent and significant reduction of NK cells in both early and advanced tumor stages compared to normal tissue is a critical finding. NK cells are crucial for innate anti-tumor surveillance and directly killing cancer cells. Their decrease indicates a significant weakening of the host's ability to control tumor growth from the early stages of disease PubMed search: NK cell cancer immunotherapy.
  2. Early Immunosuppression and Pro-Tumorigenic Inflammation:
    • Treg expansion: The significant increase in regulatory T cells (Tregs) in early tumor samples is a hallmark of immunosuppression. Tregs suppress effector T cell responses, thereby facilitating immune evasion by cancer cells. This suggests that the tumor microenvironment establishes an immunosuppressive milieu early in its development GeneCards: FOXP3.
    • Elevation of Th17, Th22, Th2, and Tfh cells in early tumor: These T cell subsets are associated with diverse inflammatory and immune regulatory roles. Th17 cells, while potentially having anti-tumor functions in some contexts, are often implicated in chronic inflammation, promoting tumor growth, angiogenesis, and metastasis in others. Th2 and Th22 cells are also linked to inflammation and tissue remodeling, which can create a permissive environment for tumor growth. Tfh cells help B cells, and some studies suggest their pro-tumorigenic role in certain cancers. The collective increase in these populations in early tumor could reflect an early inflammatory response that might initially attempt to contain the tumor but ultimately contributes to a pro-tumorigenic microenvironment or indicates a dysregulated immune response.
    • T_Naive cell elevation: The increased proportion of naive T cells in tumor conditions might suggest a failure of these cells to be properly activated and differentiated into effective anti-tumor effector cells within the tumor microenvironment, or potentially an increased recruitment without subsequent differentiation.
  3. Shifts in Advanced Disease:
    • Th2 decline in advanced tumor: While elevated in early tumor, Th2 cells significantly decrease in advanced tumor. This shift might indicate an evolving immune landscape, possibly moving away from a Type 2 inflammatory response in later stages, though the overall environment remains immunosuppressive given the persistent low NK cells and potentially high Tregs (though not statistically significant difference vs. normal in adv tumor for Treg).
    • ILC2 reduction in advanced tumor: ILC2s are typically associated with type 2 immunity and tissue repair. Their significant decrease in advanced tumor suggests a profound alteration of the immune composition, potentially signaling a loss of a specific regulatory or protective component in later stage disease, or a shift towards an ILC composition that is less responsive to type 2 stimuli.

Clinical or Translational Implications

These findings have several potential clinical implications for lung cancer:

  1. Biomarkers for Early Detection and Prognosis: The observed changes in NK cells and Tregs from early stages could serve as potential biomarkers for early lung cancer detection or for stratifying patient prognosis. A lower NK cell count or a higher Treg proportion could indicate a less favorable immune response.
  2. Immunotherapeutic Targets:
    • Restoring NK cell function: Strategies to enhance NK cell numbers or activity (e.g., NK cell adoptive transfer, cytokines like IL-15, or checkpoint inhibitors that also benefit NK cells) could be particularly beneficial for lung cancer patients, given their early and sustained depletion.
    • Treg modulation: Therapies aimed at depleting or reprogramming Tregs (e.g., specific antibodies, low-dose cyclophosphamide) could help re-activate anti-tumor T cell responses, especially in early disease.
    • Targeting specific T helper subsets: Understanding the precise pro- or anti-tumorigenic functions of Th17, Th22, and Tfh cells in lung cancer is crucial. If they are confirmed to contribute to tumor progression, targeting these pathways could be considered.
  3. Monitoring Treatment Response: Changes in the proportions of these immune cell subsets could be monitored during treatment to assess therapeutic efficacy or identify resistance mechanisms. For instance, an increase in NK cells or a decrease in Tregs post-therapy could indicate a positive response.

9. Macrophage Subset Population Dynamics in Lung Cancer Progression

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the relative proportions of different macrophage subsets (M1, M2A, M2B, M2C, M2D) across individual samples. These samples are grouped by conditions: Normal, Tumor(early), and Tumor(adv). The primary objective is to investigate how the composition of macrophage populations changes in the lung tissue microenvironment during different stages of lung cancer.

Visual Summary

The stacked bar plots display the percentage contribution of each macrophage subset to the total macrophage population per sample, categorized by disease condition:

Overall Trend: A consistent shift from a predominantly M1-polarized macrophage population in normal lung tissue to an increased prevalence of M2-like macrophage subsets (M2A, M2B, M2C) is evident in both early and advanced lung cancer conditions. This suggests a progressive re-polarization of macrophages within the tumor microenvironment.

Biological Interpretation

Macrophages are highly plastic immune cells that play a critical role in orchestrating the immune response and influencing disease progression, particularly in cancer. They polarize into distinct functional phenotypes, broadly categorized as M1 (pro-inflammatory, anti-tumorigenic) and M2 (anti-inflammatory, pro-tumorigenic).

The observed shift from M1 dominance in normal lung tissue to a higher proportion of M2-like macrophages (M2A, M2B, M2C) in lung cancer samples—both early and advanced stages—is a hallmark of the tumor microenvironment (TME). This re-education of macrophages is often driven by signals from tumor cells and other stromal components, leading to the generation of Tumor-Associated Macrophages (TAMs) which typically exhibit M2-like characteristics.

Clinical or Translational Implications

The distinct changes in macrophage subset populations observed in lung cancer have several important clinical and translational implications:

10. Macrophage Subset Population Dynamics in Lung Cancer Progression

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional changes of specific macrophage subsets (Mac (M2B), Mac (M2A), and Mac (M2C)) across different lung conditions: Tumor(early), Normal, and Tumor(adv). The goal is to identify statistically significant shifts in these immune cell populations during lung cancer progression, providing insights into their potential roles in tumor development and microenvironment modulation.

Visual Summary

The box plots illustrate the celltype proportion for three macrophage subsets across the three conditions.

Mac (M2B):

Mac (M2A):

Mac (M2C):

Biological Interpretation

Macrophages are critical components of the tumor microenvironment (TME) and often polarize into distinct functional subsets, primarily M1 (pro-inflammatory, anti-tumor) and M2 (anti-inflammatory, pro-tumor) phenotypes, though this is a simplification of a spectrum of states [1]. The observed changes in M2 macrophage subsets here provide specific insights for Lung Cancer:

  1. Mac (M2B) Expansion in Advanced Lung Cancer: The most prominent finding is the significant enrichment of Mac (M2B) cells in advanced lung tumors. M2B macrophages are known to be induced by immune complexes and Toll-like receptor (TLR) agonists, and they play roles in immune regulation, antigen presentation, and can contribute to both pro-inflammatory and pro-resolving processes depending on context [2]. In the context of cancer, an increase in certain M2 subsets, including M2B-like phenotypes, is often associated with immune suppression, tumor growth, angiogenesis, and metastasis. The late-stage expansion suggests that Mac (M2B) cells might be particularly important in promoting tumor progression in established, advanced lung cancer.
  2. Decreased Mac (M2A) and Mac (M2C) in Tumors: Surprisingly, both Mac (M2A) and Mac (M2C) subsets show decreased proportions in tumor conditions, especially in advanced stages, compared to normal tissue.
    • Mac (M2A) are typically associated with wound healing, tissue repair, and allergic responses, often considered highly pro-tumorigenic [1]. Their decrease might indicate a shift in the dominant pro-tumoral macrophage populations within this specific lung cancer TME, or a re-polarization of these cells into other states (e.g., M2B or other undefined macrophage phenotypes not captured by these subsets). It's possible that the initial recruitment or activation of M2A and M2C macrophages might be transient or that the tumor actively suppresses their specific phenotype while promoting others.
    • Mac (M2C) are characterized by their immunosuppressive and pro-fibrotic activities, often involved in tissue remodeling and efferocytosis, and are generally considered highly protumorigenic [1]. Their decrease is also unexpected but could similarly point to a dynamic TME where certain M2-like functions are either taken over by other cell types/states or are less prominent in this particular cancer context compared to other M2 phenotypes.

These findings suggest a dynamic and potentially complex macrophage polarization landscape in Lung Cancer, where specific M2 subsets might be selectively promoted or suppressed at different disease stages. The pronounced increase in Mac (M2B) in advanced tumors, while other M2 subsets decrease, highlights a potentially distinct macrophage polarization pattern driving lung cancer progression.

Clinical or Translational Implications

References

  1. Locati, M., et al. (2020). Macrophage Polarization and Repolarization in Tissue Repair and Fibrosis. *Trends in Immunology*, 41(3), 261-274. PubMed Search: Macrophage polarization cancer
  2. Mantovani, A., et al. (2004). The chemokine system in cancer biology and therapy. *Nature Reviews Immunology*, 4(9), 682-692. PubMed Search: M2B macrophages cancer

11. Ploidy Analysis of Tumor-Origin Lung Epithelial Cells Across Disease Stages

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the ploidy status (Aneuploid, Diploid, Unclear) of Lung Epithelial cells, identified as the tumor-origin cell type, across different conditions: Normal, Tumor (advanced), and Tumor (early). The results are presented as stacked bar plots for individual samples within each condition, showing the proportion of cells belonging to each ploidy category.

Visual Summary

The visualization clearly illustrates distinct ploidy patterns among the three conditions:

Biological Interpretation

The observed ploidy patterns provide strong biological insights consistent with lung cancer pathology, given that Lung Epithelial cells are identified as the tumor-origin cell type:

Clinical or Translational Implications

The findings from this ploidy analysis have several potential clinical and translational implications for lung cancer:

12. Cell-Cell Interaction Patterns Across Lung Cancer Progression

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis characterizes cell-cell interaction (CCI) patterns among key cellular components of the lung microenvironment: Lung Epithelial cells (both diploid and aneuploid), Macrophages, and T cells (CD4+ and CD8+ subsets). These interactions are evaluated across normal lung tissue, early-stage lung tumors, and advanced-stage lung tumors, utilizing CellPhoneDB methodology. The primary goal is to identify how cellular communication changes during lung cancer progression, with a focus on interactions relevant to tumor development, immune response, and the tumor microenvironment (TME). The visualization presents the top 80 significant interactions, ranked by significance and mean expression, for each condition.

Visual Summary

The dot plots illustrate significant ligand-receptor interactions across various cell type pairs and conditions. The size of each dot reflects the statistical significance (-log10(p-value)), while the color indicates the mean expression level (log2(mean)) of the ligand-receptor pair.

  1. Emergence of Aneuploid Lung Epithelial Cell Interactions in Tumor Conditions: In the "Normal" condition, interactions primarily involve Diploid Lung Epithelial cells. With the onset of "Tumor(early)" and "Tumor(adv)" conditions, Aneuploid Lung Epithelial cells (the likely malignant population) become prominent interactors, forming distinct communication networks with immune cells (Macrophages, T cells) and other epithelial cells.
  2. Condition-Specific Interaction Landscapes:
    • Normal: Characterized by diverse interactions involving Diploid Lung Epithelial cells, Macrophages, and T cells, including significant HLA-DR_complex interactions between Macrophages and T cells, and between Macrophages and Diploid Lung Epithelial cells. Strong APOE_TREM2 interactions are notable within Macrophages and between Macrophages and Diploid Lung Epithelial cells.
    • Tumor (early and advanced): A noticeable shift occurs, with a general increase in interactions involving integrin complexes (e.g., FN1_integrin_a2b1_complex, ICAM1_integrin_M2_complex, integrin_avB1_complex_ADGRES), EGFR_EGFR, VEGFA family ligands, and TGFB1 signaling, particularly with Aneuploid Lung Epithelial cells.
  3. Key Interaction Changes Across Stages:
    • Immune Interactions: HLA-DR_complex interactions involving Aneuploid Lung Epithelial cells appear reduced or altered in tumor conditions compared to Diploid Lung Epithelial cells in normal tissue, potentially indicative of immune evasion. CD47_CD47 interactions (representing homophilic binding or complexes involving CD47) are present across conditions, notably involving Macrophages and Lung Epithelial cells in tumor.
    • Adhesion and ECM Remodeling: Integrin mediated interactions (e.g., FN1_integrin_a2b1_complex, FN1_integrin_avB1_complex, ICAM1_integrin) are broadly active and appear sustained or enhanced in tumor conditions, involving Aneuploid Lung Epithelial cells, Macrophages, and T cells, suggesting active roles in adhesion, migration, and extracellular matrix (ECM) remodeling.
    • Growth Factor Signaling: EGFR_EGFR and VEGFA interactions (e.g., VEGFA_VEGFR1, VEGFA_VEGFR2) are consistently strong in tumor conditions, especially involving Aneuploid Lung Epithelial cells and Macrophages, highlighting their roles in tumor proliferation and angiogenesis.
    • Immunosuppression and Fibrosis: TGFB1_TGFBR1_TGFBR2_complex interactions are observed in tumor conditions, suggesting active TGF-β signaling, known for its roles in immunosuppression and fibrosis within the TME.
  4. Fibroblast Interactions: While 'Fibroblast' was among the requested cell types for interaction analysis, its specific interactions are not prominently displayed on the y-axis in these top 80 plots. This suggests that the strongest and most significant interactions involved the other specified cell types (Lung Epithelial, Macrophage, T cells).

Biological Interpretation

The observed shifts in cell-cell interactions provide critical insights into the evolving lung cancer microenvironment.

Tumor-Promoting Microenvironment

Clinical or Translational Implications

These findings have significant implications for understanding lung cancer progression and identifying potential therapeutic targets.

References

  1. CD47-SIRPA Axis: Genes, Structure, and Function. GeneCards: https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD47
  2. VEGF Signaling in Cancer: PubMed Search: https://pubmed.ncbi.nlm.nih.gov/?term=VEGF+signaling+cancer
  3. Integrins in Cancer: PubMed Search: https://pubmed.ncbi.nlm.nih.gov/?term=integrins+cancer+lung
  4. TGF-beta in Cancer: PubMed Search: https://pubmed.ncbi.nlm.nih.gov/?term=TGF-beta+signaling+lung+cancer+immunotherapy

13. Cell-Cell Interaction Analysis of Immune Checkpoint and Cell Cycle Pathways in Lung Cancer Progression

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interactions (CCI) mediated by a curated set of genes associated with immune checkpoint and cell cycle pathways across Normal lung tissue, early-stage (Tumor(early)), and advanced-stage (Tumor(adv)) lung cancer. The plot_cci_dots tool was used to visualize the most significant and strongest ligand-receptor interactions, with dot size representing significance (-log10(p-value)) and color intensity representing interaction strength (log2(mean expression)). The analysis focuses on understanding how these critical pathways contribute to the tumor microenvironment and progression, particularly involving tumor-origin Lung Epithelial cells and various immune cells.

Visual Summary

The dot plots reveal distinct patterns of cell-cell interactions across the three conditions (Normal, Tumor(early), Tumor(adv)) for the selected immune checkpoint and cell cycle-related genes:

  1. Normal Condition:
    • Autocrine EGFR signaling (AREG-EGFR, EREG-EGFR) is prominently observed within "Diploid Lung Epi" cells, indicating basal growth factor activity.
    • Immune cell interactions are present, including LCK_CD8_receptor within "T CD8+" T cells and between "T CD8+" and "Mac" cells, as well as CD93-IFNGR1 and TGFB1-TGFbeta_receptor3 within "Mac" cells.
    • An interaction between "Mac" and "Diploid Lung Epi" cells via IFNG-Type_II_IFNR suggests immune surveillance or regulatory cross-talk.
  2. Tumor(early) Condition:
    • A striking increase in autocrine EGFR signaling (AREG-EGFR, HBEGF-EGTR, EREG-EGFR, TGFA-EGFR) is observed within "Aneuploid Lung Epi" cells, indicating early activation of this pro-growth pathway in tumor cells.
    • Paracrine EGFR signaling also emerges, with "Aneuploid Lung Epi" interacting with "T CD8+" and "Mac" cells through EREG-EGFR and TGFA-EGFR.
    • TGFB1-TGFbeta_receptor1 and TGFB1-TGFbeta_receptor2 interactions become evident within "Aneuploid Lung Epi" cells.
    • Immune cell interactions like LCK_CD8_receptor (T CD8+|T CD8+) and CD93-IFNGR1 (Mac|Mac) persist.
  3. Tumor(adv) Condition:
    • The expansion and intensity of EGFR signaling (AREG-EGFR, HBEGF-EGTR, EREG-EGFR, TGFA-EGFR) within "Aneuploid Lung Epi" cells and between "Aneuploid Lung Epi" cells and immune cells ("T CD8+", "Mac") become even more pronounced compared to the early tumor stage, suggesting its sustained importance in advanced disease.
    • TGFB1 signaling shows further diversification and strength, with interactions such as TGFB1-TGFbeta_receptor1, TGFB1-TGFbeta_receptor2, and TGFB1-integrin_avb6_complex prominent in "Aneuploid Lung Epi" autocrine loops and between "Mac" and "Aneuploid Lung Epi" cells.
    • Immune cell interactions like LCK_CD8_receptor and CD93-IFNGR1 remain, but the overall landscape is dominated by tumor-related growth factor signaling.
    • Notably, classic immune checkpoint interactions (e.g., PDCD1-CD274, i.e., PD-1/PD-L1) are not among the top 80 most significant interactions displayed, despite these genes being included in the target list.

Biological Interpretation

The observed shifts in cell-cell interactions provide key biological insights into lung cancer progression:

Clinical or Translational Implications

The findings highlight several areas with significant clinical and translational relevance:

14. Condition-Specific Cell-Cell Interaction Patterns in Lung Cancer

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates condition-specific cell-cell interaction (CCI) patterns involving major immune and stromal cell types (T cell, Myeloid cell, B cell, Mast cell, Stromal cell, Endothelial cell) across Normal, Tumor(adv) (advanced tumor), and Tumor(early) (early tumor) conditions in human lung tissue. The dot plot visualizes the strength (scaled log strength, color intensity) and statistical significance (-log10(p), dot size) of various ligand-receptor interactions between specified cell pairs, sorted by minimum p-value within each condition. The goal is to identify interactions that are significantly different between conditions, providing insight into the evolving tumor microenvironment in lung cancer.

Visual Summary

The dot plot displays a complex landscape of cell-cell interactions, with distinct patterns emerging across the Normal, Tumor(adv), and Tumor(early) conditions.

Biological Interpretation

The observed condition-specific CCI patterns underscore profound alterations in the lung tumor microenvironment (TME) compared to normal tissue.

Interactions Dominant in Normal Lung Tissue

In the Normal condition, many significant interactions are observed, suggesting a well-regulated and homeostatic microenvironment.

Interactions Enriched in Tumor Conditions

In contrast to normal tissue, tumor conditions (Tumor(adv) and Tumor(early)) show the emergence or increased prominence of interactions that promote tumor progression.

Clinical or Translational Implications

The differential CCI patterns between normal and cancerous lung tissue highlight potential diagnostic, prognostic, and therapeutic opportunities in lung cancer.

These findings provide a basis for further experimental validation and drug development efforts aimed at precisely modulating the lung cancer microenvironment.

15. Lung Epithelial Cell Surfaceome Marker Expression in Lung Cancer

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes the expression of surfaceome markers in Lung Epithelial cells across different conditions (Normal, Tumor(adv), Tumor(early)) and ploidy states (Diploid, Aneuploid). The objective is to identify cell-type and condition-specific markers, particularly those enriched in aneuploid tumor cells, which could represent established or potential therapeutic targets for lung cancer. The dot plot displays mean expression levels (color intensity) and the fraction of cells expressing each marker (dot size) for individual samples.

Visual Summary

The dot plot, titled "Lung Epithelial cell condition-specific markers," effectively illustrates distinct expression profiles between normal and tumor-associated lung epithelial cells, and notably between diploid and aneuploid cells within the tumor microenvironment.

Biological Interpretation

The differential expression of surfaceome markers provides critical insights into the molecular landscape of lung cancer and identifies potential targets for therapeutic intervention.

Established Therapeutic Targets

Several identified markers are well-known therapeutic targets in lung cancer, confirming their relevance in this dataset's tumor cells:

EGFR (Epidermal Growth Factor Receptor)

ERBB2 (HER2 - Human Epidermal Growth Factor Receptor 2)

MET (MET Receptor Tyrosine Kinase)

Less Well-Characterized Markers with Potential as Therapeutic Targets

The analysis also highlights markers that are significantly upregulated in aneuploid tumor cells but are not yet as extensively targeted clinically in lung cancer, representing potential novel therapeutic avenues:

CD24 (Cluster of Differentiation 24)

CD276 (B7-H3)

ITGA3 (Integrin alpha-3)

Clinical or Translational Implications

The identification of these surfaceome markers in aneuploid Lung Epithelial cells has significant clinical and translational implications for lung cancer:

16. sdk_http_response=HttpResponse(

Report figure

[Analysis Visualization Results]...

headers=<dict len=12>

) candidates=[Candidate(

content=Content(

role='model'

),

finish_reason=<FinishReason.STOP: 'STOP'>,

index=0

)] create_time=None model_version='gemini-2.5-flash' prompt_feedback=None response_id='fkXLatTuAcDgrfcPg4WK8Ao' usage_metadata=GenerateContentResponseUsageMetadata(

prompt_token_count=3475,

prompt_tokens_details=[

ModalityTokenCount(

modality=<MediaModality.TEXT: 'TEXT'>,

token_count=3217

),

ModalityTokenCount(

modality=<MediaModality.IMAGE: 'IMAGE'>,

token_count=258

),

],

thoughts_token_count=8621,

total_token_count=12096

) automatic_function_calling_history=[] parsed=None

17. Fibroblast Condition-Specific Surfaceome Markers in Lung Cancer

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies condition-specific surfaceome markers for Fibroblast cells, comparing Normal and Tumor(early) lung tissue samples from single-cell RNA-seq data. The goal is to highlight differences in cell surface protein expression that may indicate altered fibroblast function in the early tumor microenvironment (TME) of lung cancer, and to identify potential therapeutic targets. The plot_markers_and_expression_dot tool was used to visualize the expression of up to 40 surfaceome markers per condition, ranked by a differential expression score.

Visual Summary

The dot plot visualizes the expression of 36 surfaceome markers in Fibroblast cells across various individual samples, categorized by their tissue origin (Normal vs. Tumor(early)).

Condition-Specific Patterns:

Biological Interpretation

Fibroblasts are crucial components of the lung tumor microenvironment (TME), evolving into cancer-associated fibroblasts (CAFs) that promote tumor growth, invasion, metastasis, and immune evasion. The observed differential expression of surfaceome markers in Fibroblasts transitioning from Normal to Tumor(early) conditions provides insights into their changing functions in early lung cancer. The shift towards markers involved in ECM remodeling, cell adhesion, and signaling pathways signifies the activation and reprogramming of fibroblasts into a pro-tumorigenic state.

Markers Predominantly Expressed in Normal Fibroblasts:

  1. GPNMB (Glycoprotein NMB)
    • Signaling Pathways: Interacts with integrins and CD44. Involved in cell adhesion, migration, and differentiation. Can suppress inflammation and regulate osteoblast differentiation.
    • Role in TME: While often associated with mesenchymal stem cells and some cancers, its higher expression in normal fibroblasts might indicate roles in tissue homeostasis, ECM organization, or immune regulation distinct from a pro-tumorigenic CAF.
    • Therapeutic Target Potential: Has been explored as a target in melanoma and breast cancer (e.g., glembatumumab vedotin antibody-drug conjugate). Its role in normal lung fibroblasts may suggest potential for targeting specific cancer cell types rather than general stromal components in lung.
    • Therapeutic Agents: Glembatumumab vedotin (targeting GPNMB) has been in clinical trials for other cancers.
    • Other Information: Can be associated with a more differentiated, quiescent fibroblast state in healthy tissue. GeneCards: GPNMB
  2. ABCA8 (ATP Binding Cassette Subfamily A Member 8)
    • Signaling Pathways: Functions as a lipid transporter, specifically for sterols. Involved in cellular lipid homeostasis.
    • Role in TME: Its higher expression in normal fibroblasts suggests a role in maintaining normal lipid metabolism within the healthy lung stroma. Altered lipid metabolism is a hallmark of cancer, so its downregulation or different regulation in tumor fibroblasts could be significant.
    • Therapeutic Target Potential: Direct targeting of ABCA8 in cancer is less established. However, understanding lipid metabolism changes in CAFs could offer indirect therapeutic strategies.
    • Therapeutic Agents: No specific therapeutic agents directly targeting ABCA8 are widely known for cancer.
    • Other Information: Belongs to the ABC transporter family, critical for diverse physiological processes. GeneCards: ABCA8
  3. TSPAN8 (Tetraspanin 8)
    • Signaling Pathways: Tetraspanins form microdomains on the cell surface, influencing receptor signaling (e.g., integrins, growth factor receptors) and cell-cell/cell-matrix interactions.
    • Role in TME: In various cancers, TSPAN8 promotes proliferation, migration, invasion, and angiogenesis. Its higher expression in normal fibroblasts might imply a basal role in cell organization or communication in healthy tissue, which might be dysregulated or lost in the TME.
    • Therapeutic Target Potential: Tetraspanins are challenging to target directly but could influence the efficacy of other therapies.
    • Therapeutic Agents: No direct therapeutic agents for TSPAN8 are currently in widespread clinical use.
    • Other Information: Can modulate other cell surface proteins, impacting their function and localization. GeneCards: TSPAN8
  4. RECK (Reversion-inducing-cysteine-rich protein with kazal motifs)
    • Signaling Pathways: A membrane-anchored matrix metalloproteinase (MMP) regulator, inhibiting the activity of MMPs (e.g., MMP2, MMP9, MMP14).
    • Role in TME: As an MMP inhibitor, RECK generally acts as a tumor suppressor by limiting ECM degradation and angiogenesis. Its expression in normal fibroblasts helps maintain tissue integrity. While grouped with normal markers, its presence, even at lower levels, in some tumor samples could represent a residual protective mechanism or heterogeneity.
    • Therapeutic Target Potential: RECK itself is not typically a target, but its activity implies that its downregulation in CAFs contributes to aggressive tumor behavior by increasing MMP activity. Modulating MMPs directly or indirectly could be a strategy.
    • Therapeutic Agents: None directly targeting RECK. MMP inhibitors have been explored but faced challenges.
    • Other Information: Plays a role in maintaining tissue integrity and has anti-angiogenic properties. GeneCards: RECK
  5. CDH11 (Cadherin 11 / OB-cadherin)
    • Signaling Pathways: Calcium-dependent cell-cell adhesion molecule. Involved in epithelial-mesenchymal transition (EMT), cell migration, and tissue morphogenesis.
    • Role in TME: CDH11 promotes CAF activation, migration, and invasiveness in some cancers. Its presence in normal fibroblasts may reflect its role in maintaining specific tissue architecture, whereas its altered regulation or ligand binding in CAFs could contribute to TME remodeling.
    • Therapeutic Target Potential: CDH11 has been considered as a target for modulating CAF function and tumor progression.
    • Therapeutic Agents: Inhibitors targeting CDH11 are under investigation in preclinical settings.
    • Other Information: Plays a significant role in rheumatoid arthritis and various cancers. GeneCards: CDH11

Other Normal Fibroblast Markers:

Markers Predominantly Expressed in Tumor(early) Fibroblasts:

  1. FAP (Fibroblast Activation Protein alpha)
    • Signaling Pathways: A serine protease and dipeptidyl peptidase. It cleaves specific ECM proteins (e.g., collagen, gelatin, fibronectin) and growth factors, modulating the TME.
    • Role in TME: A canonical marker of activated CAFs across many cancers, including lung cancer. FAP-expressing CAFs promote ECM remodeling, tumor growth, invasion, angiogenesis, and immune suppression.
    • Therapeutic Target Potential: High specificity for CAFs in solid tumors makes FAP an attractive therapeutic target.
    • Therapeutic Agents: FAP-targeting agents, including antibodies (e.g., sibrotuzumab), antibody-drug conjugates (ADCs), and FAP-targeted radioligands (e.g., FAPI), are under investigation in preclinical and clinical trials. PubMed: FAP cancer therapy
    • Other Information: Its elevated expression in early tumor samples suggests that CAF activation is an early event in lung cancer progression. GeneCards: FAP
  2. MMP14 (Matrix Metallopeptidase 14 / MT1-MMP)
    • Signaling Pathways: A membrane-anchored MMP that degrades various ECM components (e.g., collagen, fibronectin). Activates other MMPs (e.g., MMP2).
    • Role in TME: Critically involved in ECM degradation, promoting tumor cell invasion, angiogenesis, and metastasis. CAFs often upregulate MMP14 to remodel the TME and facilitate tumor progression.
    • Therapeutic Target Potential: Given its central role in invasion and metastasis, MMP14 is a promising target.
    • Therapeutic Agents: MMP inhibitors have faced challenges in clinical trials due to broad specificity, but more selective MMP14 inhibitors are being developed.
    • Other Information: Essential for physiological processes but highly dysregulated in cancer. GeneCards: MMP14
  3. Integrins (ITGAV, ITGB5, ITGA1, ITGA8)
    • Signaling Pathways: Heterodimeric cell surface receptors (alpha and beta subunits, e.g., ITGAV pairs with ITGB5 to form $\alpha_V\beta_5$) that mediate cell-ECM adhesion and transmit bidirectional signals (outside-in and inside-out).
    • Role in TME: Integrins on CAFs are crucial for mechanosensing, maintaining CAF contractility, promoting ECM stiffness, and signaling pathways that drive CAF activation, proliferation, and interaction with tumor cells and immune cells. $\alpha_V$ integrins (e.g., $\alpha_V\beta_5$) are particularly important in fibrosis and cancer.
    • Therapeutic Target Potential: Integrins are well-established targets, especially $\alpha_V$ integrins, for anti-angiogenic and anti-fibrotic therapies, relevant for TME modulation.
    • Therapeutic Agents: Integrin inhibitors (e.g., cilengitide targeting $\alpha_V\beta_3$ and $\alpha_V\beta_5$) have been tested in clinical trials for various cancers.
    • Other Information: The upregulation of multiple integrin subunits (ITGAV, ITGB5, ITGA1, ITGA8) in early tumor fibroblasts highlights their central role in the physical and biochemical properties of the early lung cancer TME. GeneCards: ITGAV ; GeneCards: ITGB5
  4. VCAM1 (Vascular Cell Adhesion Molecule 1)
    • Signaling Pathways: A cell surface glycoprotein that mediates cell-cell adhesion, primarily through binding to VLA-4 (integrin $\alpha_4\beta_1$) on immune cells.
    • Role in TME: VCAM1 on CAFs can facilitate the recruitment and adhesion of immune cells (e.g., monocytes, lymphocytes) and tumor cells, promoting inflammation, immune evasion, and metastasis. It can also support angiogenesis.
    • Therapeutic Target Potential: VCAM1 is a potential target to disrupt tumor-stromal and tumor-immune interactions.
    • Therapeutic Agents: Antibodies targeting VCAM1 or its ligand VLA-4 (e.g., natalizumab for autoimmune diseases) exist, but specific cancer therapies are largely preclinical.
    • Other Information: Its expression is often induced by inflammatory cytokines. GeneCards: VCAM1
  5. NOTCH2 (Notch Receptor 2)
    • Signaling Pathways: Part of the highly conserved Notch signaling pathway, which regulates cell fate decisions, proliferation, differentiation, and apoptosis through direct cell-cell contact.
    • Role in TME: Notch signaling in CAFs can promote their activation, self-renewal, and pro-tumorigenic functions, influencing ECM remodeling, angiogenesis, and immune suppression in the TME.
    • Therapeutic Target Potential: Notch signaling is dysregulated in many cancers, and targeting Notch receptors or their ligands is an area of active research.
    • Therapeutic Agents: Gamma-secretase inhibitors (GSIs), which block Notch pathway activation, are in clinical development for various cancers, though with challenges due to on-target toxicities. Antibodies targeting specific Notch receptors are also being explored.
    • Other Information: The presence of NOTCH2 in early tumor fibroblasts suggests the early activation of developmental pathways in the TME. GeneCards: NOTCH2
  6. SPINT2 (Serine Peptidase Inhibitor, Kunitz Type 2 / HAI-2)
    • Signaling Pathways: A Kunitz-type serine protease inhibitor that inhibits certain proteases, including matriptase and hepsin. These proteases are involved in activating growth factors and regulating cell adhesion.
    • Role in TME: SPINT2 can regulate the activity of proteases involved in ECM degradation and growth factor activation. Its upregulation in CAFs could represent a complex regulatory mechanism, potentially either promoting or limiting certain proteolytic activities, depending on the specific TME context. In some cancers, it can suppress invasion by inhibiting matriptase.
    • Therapeutic Target Potential: Modulating protease activity through inhibitors like SPINT2 is a complex but potential strategy.
    • Therapeutic Agents: No direct therapeutic agents for SPINT2.
    • Other Information: Can function as a tumor suppressor by controlling membrane-bound protease activity. GeneCards: SPINT2
  7. CD82 (KAI1)
    • Signaling Pathways: A member of the tetraspanin family. It interacts with other tetraspanins, integrins, and growth factor receptors to form multimolecular complexes on the cell surface, modulating cell migration, adhesion, and signal transduction.
    • Role in TME: Often considered a metastasis suppressor gene; its loss is associated with increased invasiveness and metastasis in many cancers. However, its role can be context-dependent, and its expression on CAFs might influence their interactions with tumor cells or immune cells.
    • Therapeutic Target Potential: Re-expression or potentiation of CD82 activity has been explored as a strategy.
    • Therapeutic Agents: No specific therapeutic agents targeting CD82 are widely used.
    • Other Information: Can inhibit growth factor signaling and promote apoptosis. GeneCards: CD82

Other Tumor(early) Fibroblast Markers:

Clinical or Translational Implications

The distinct surfaceome profiles of normal versus early tumor fibroblasts highlight critical changes in the TME during early lung cancer development.

Therapeutic Targets for CAF Depletion/Reprogramming:

18. CD4+ T Cell Condition-Specific Surface Marker Expression in Lung Cancer

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a dot plot illustrating the expression of surfaceome markers in CD4+ T cells across different conditions: Normal lung tissue, early-stage Lung Tumor (Tumor(early)), and advanced-stage Lung Tumor (Tumor(adv)). The purpose is to identify specific surface markers that distinguish the functional states or populations of CD4+ T cells in the tumor microenvironment (TME) compared to normal lung tissue. Dot size represents the fraction of cells expressing a given marker, and dot color intensity indicates the mean expression level within that cell group and sample.

Visual Summary

The dot plot clearly segregates marker expression patterns based on the tissue condition:

Biological Interpretation

The observed surface marker profiles indicate distinct functional states and roles of CD4+ T cells in normal lung tissue versus the lung tumor microenvironment.

Markers Associated with Normal Lung CD4+ T Cells

Markers Associated with Tumor-Infiltrating CD4+ T Cells

The robust upregulation of a specific set of surface markers in CD4+ T cells from both early and advanced tumors suggests adaptive responses within the immunosuppressive tumor microenvironment, reflecting activation, differentiation, exhaustion, and altered trafficking.

Immune Checkpoints and Co-stimulatory/Co-inhibitory Molecules:

Cell Adhesion and Migration Molecules:

Other Notable Markers:

Clinical or Translational Implications

The identification of these surface markers in CD4+ T cells offers several potential clinical and translational avenues for Lung Cancer:

Therapeutic Targets (Immune Checkpoints/Co-stimulatory Molecules):

Diagnostic and Prognostic Biomarkers:

Experimental Validation:

19. Differential Expression of Cell Cycle Genes in Lung Epithelial Cells Across Tumor Progression

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the "Expressing cell fraction (sample)" for a curated set of cell cycle pathway genes within Lung Epithelial cells across different conditions: advanced tumor (Tumor(adv)), normal tissue (Normal), and early tumor (Tumor(early)). The goal is to identify genes with statistically significant expression differences that may indicate altered cell cycle regulation during lung tumorigenesis. The "Expressing cell fraction (sample)" represents the proportion of cells within each sample that express a given gene, providing insights into the prevalence of gene activity within the cell population rather than just average expression intensity. The analysis highlights 24 selected cell cycle genes that show significant differences.

Visual Summary

The box plots display the expressing cell fraction for 24 cell cycle-related genes in Lung Epithelial cells across Tumor(adv), Normal, and Tumor(early) conditions.

Key Observations:

Mixed or Downregulated Patterns:

Biological Interpretation

The observed gene expression patterns in Lung Epithelial cells provide strong evidence for deregulated cell cycle control in lung cancer, consistent with the inferred disease context.

Clinical or Translational Implications

The findings underscore the significant dysregulation of cell cycle machinery in Lung Epithelial cells during lung cancer development and progression.

20. Gene Ontology (GSA) Analysis for Lung Epithelial Cells Across Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Ontology (GO) enrichment results (GSA) for "Lung Epithelial cell" populations, comparing each specified condition (Diploid, Normal, Tumor(adv), Tumor(early)) against all other conditions combined ("others"). The plots display the top enriched GO terms (pathways/biological processes) that are significantly upregulated in each respective condition, sorted by their -log(p-val). This allows us to identify characteristic functional shifts in lung epithelial cells in different physiological and pathological states, particularly in the context of lung cancer.

Visual Summary

The four bar plots illustrate distinct patterns of Gene Ontology enrichment for Lung Epithelial cells based on their ploidy status and disease condition:

  1. Diploid_vs_others: This plot shows a strong enrichment for immune-related processes, including "Staphylococcus aureus infection," "Complement and coagulation cascades," "Phagosome," "Antigen processing and presentation," and various inflammatory and autoimmune diseases. This indicates that diploid lung epithelial cells are highly active in host defense and immune responses.
  2. Normal_vs_others: Similar to the Diploid state, Normal Lung Epithelial cells also exhibit significant enrichment in immune-related pathways such as "Phagosome," "Human T-cell leukemia virus 1 infection," "Th1 and Th2 cell differentiation," and "Inflammatory bowel disease." Additionally, pathways related to metabolism like "PPAR signaling pathway" and "Cholesterol metabolism" are prominent.
  3. Tumor(adv)_vs_others: A dramatically different profile emerges for advanced tumor cells. The most highly enriched terms are fundamental cellular processes associated with rapid growth and high metabolic demand: "Ribosome," "Spliceosome," "RNA transport," "Proteasome," "Protein processing in endoplasmic reticulum," and "Ubiquitin mediated proteolysis." "Cell cycle" is also notably enriched. Several neurodegenerative disease pathways (e.g., Parkinson's, Alzheimer's, Huntington disease) and general stress responses are also prominent.
  4. Tumor(early)_vs_others: The early tumor cell profile largely resembles that of advanced tumor cells, with robust enrichment for "Ribosome," "Spliceosome," "Protein processing in endoplasmic reticulum," and "Ubiquitin mediated proteolysis." Infection-related terms like "Salmonella infection" and various viral infections appear, along with neurodegenerative disease pathways, suggesting an early onset of cellular stress and dysregulation of core cellular machinery.

Biological Interpretation

The GSA results reveal a profound shift in the functional landscape of Lung Epithelial cells as they transition from normal/diploid states to early and advanced tumor stages.

Clinical or Translational Implications

These findings have several important clinical and translational implications for lung cancer:

---

References

  1. Ribosome biogenesis in cancer:

PubMed Search: ribosome biogenesis cancer

  1. Spliceosome in cancer:

PubMed Search: spliceosome cancer

  1. ER stress and proteostasis in cancer:

PubMed Search: ER stress cancer proteostasis

  1. Proteasome inhibitors in cancer:

PubMed Search: proteasome inhibitors cancer

21. Gene Set Enrichment Analysis of Lung Cancer Cell Types

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Set Enrichment Analysis (GSEA) results, visualized as a dot plot, for various cell types in lung tissue. The comparison is performed for different conditions, specifically "Normal," "Tumor(early)," and "Tumor(adv)," against all other conditions combined (e.g., "B cell: Normal_vs_others"). The plot illustrates the Normalized Enrichment Score (NES) using a divergent color map (red for positive/upregulated enrichment, blue for negative/downregulated enrichment) and the statistical significance (-log(p-value)) through the size of the dots (larger dots indicate higher significance). This approach enables the identification of functionally relevant pathways and biological processes that are differentially regulated across distinct cell populations during lung cancer progression. The analysis encompasses a wide array of biological pathways, including those involved in immune responses, metabolic shifts, cell proliferation, and key signaling cascades.

Visual Summary

The GSEA dot plot provides a comprehensive overview of pathway activity across different cell types and disease conditions, revealing several key patterns:

Condition-Dependent Pathway Activation:

Cell Type-Specific Pathway Dysregulation:

Stromal Cells (Fibroblasts, Endothelial cells):

Biological Interpretation

The Gene Set Enrichment Analysis results provide critical biological insights into the molecular mechanisms driving lung cancer progression, encompassing both the transformed epithelial cells and the surrounding tumor microenvironment (TME).

  1. Oncogenic Transformation and Progression in Lung Epithelial Cells:
    • The prominent and progressive enrichment of pathways such as 'Pathways in cancer', 'HIF-1 signaling pathway', 'VEGF signaling pathway', 'MAPK signaling pathway', and 'TGF-beta signaling pathway' in Lung Epithelial cells from early to advanced tumor stages directly reflects their malignant transformation. These pathways are fundamental regulators of cell proliferation, survival, metabolic reprogramming (e.g., adaptation to hypoxia via HIF-1 signaling), and angiogenesis, all hallmarks of cancer GeneCards - MAPK1, GeneCards - TGFB1.
  2. Dynamic Immune Landscape in the Tumor Microenvironment:
    • T Cell Activation and Evasion: The upregulation of 'T cell receptor signaling pathway', 'Th1 and Th2 cell differentiation', 'Th17 cell differentiation', and 'JAK-STAT signaling pathway' in tumor-associated T cells suggests an ongoing, albeit complex, anti-tumor immune response. However, the strong and widespread enrichment of 'PD-L1 expression and PD-1 checkpoint pathway in cancer' in both CD4+ and CD8+ T cells within tumor conditions (especially advanced) is a crucial finding. This indicates the activation of immune evasion mechanisms, where T cell effector functions are likely suppressed via the PD-1/PD-L1 axis, a well-established mechanism of immune escape in various cancers, including lung cancer PubMed search - PD-1 PD-L1 immune evasion lung cancer.
    • Myeloid Cell Reprogramming: Macrophages and Dendritic cells in the TME show enrichment for 'HIF-1 signaling pathway', 'Chemokine signaling pathway', 'NF-kappa B signaling pathway', and 'Phagosome'. This profile suggests their activation and potential polarization towards pro-tumorigenic phenotypes, such as tumor-associated macrophages (TAMs), which contribute to immunosuppression, angiogenesis, and tumor growth. The observed downregulation of 'Oxidative phosphorylation' in 'Macrophage: Tumor(adv)_vs_others' aligns with metabolic reprogramming often seen in TAMs, favoring glycolysis to support their altered functions.
  3. Critical Role of Stromal Cells in Tumor Support:
    • Cancer-Associated Fibroblasts (CAFs): The pronounced enrichment of 'TGF-beta signaling pathway', 'HIF-1 signaling pathway', 'MAPK signaling pathway', and 'VEGF signaling pathway' in tumor-associated fibroblasts underscores their critical role in promoting tumor progression. CAFs are known to remodel the extracellular matrix, secrete growth factors, and influence immune cells, thereby fostering cancer cell proliferation, invasion, and metastasis PubMed search - Cancer Associated Fibroblasts Lung Cancer microenvironment.
    • Angiogenesis by Endothelial Cells: The strong and progressively activated 'VEGF signaling pathway', 'HIF-1 signaling pathway', and 'MAPK signaling pathway' in endothelial cells from early to advanced tumor stages clearly indicates active angiogenesis. This process is indispensable for establishing the vascular network required to supply oxygen and nutrients to the rapidly expanding tumor mass GeneCards - VEGFA.
  4. Metabolic Reprogramming Across the TME: The divergent patterns in metabolic pathways (e.g., 'Oxidative phosphorylation' downregulation in some tumor-associated immune/stromal cells) highlight a broader metabolic reprogramming not just within cancer cells but also within their supporting TME cells. This adaptation is crucial for meeting the high energy demands of proliferating tumor cells and for modulating immune cell function.

Clinical or Translational Implications

The detailed GSEA findings across multiple cell types and disease stages in lung cancer provide actionable insights for clinical and translational applications:

  1. Refined Therapeutic Targeting: The consistent activation of key oncogenic pathways like 'HIF-1 signaling pathway', 'VEGF signaling pathway', 'MAPK signaling pathway', and 'TGF-beta signaling pathway' in tumor-originating Lung Epithelial cells reinforces these as prime candidates for targeted therapies. Developing or repurposing inhibitors against these pathways could directly impede cancer cell growth and survival.
  2. Optimizing Immunotherapy Strategies: The prominent upregulation of the 'PD-L1 expression and PD-1 checkpoint pathway in cancer' in T cells within the tumor microenvironment strongly supports the continued and strategic use of immune checkpoint blockade (e.g., anti-PD-1/PD-L1 therapies) in lung cancer. The observed increase in this pathway's activity in advanced stages might suggest different efficacy or patient selection criteria as the disease progresses. Further research could explore combination therapies that address other immunosuppressive pathways identified.
  3. Targeting the Tumor Microenvironment for Enhanced Efficacy:
    • Anti-angiogenic Therapies: The clear and progressive activation of 'VEGF signaling pathway' in endothelial cells from early to advanced tumors highlights the ongoing relevance of anti-angiogenic strategies to starve tumor growth by cutting off blood supply.
    • CAF-Modulating Therapies: The significant involvement of 'TGF-beta signaling pathway' and other pro-tumorigenic pathways in fibroblasts indicates that targeting CAFs could be a promising approach to disrupt the supportive tumor-stromal interactions, potentially inhibiting tumor invasion and metastasis, and improving the efficacy of existing treatments.
  4. Biomarker Discovery and Patient Stratification: The identified cell-type-specific and stage-dependent pathway alterations could serve as valuable biomarkers for predicting disease progression, patient prognosis, or responsiveness to specific therapies. For example, the expression levels of genes within the 'PD-L1 expression and PD-1 checkpoint pathway' in tumor-infiltrating T cells could help stratify patients who would benefit most from immunotherapy.
  5. Understanding Treatment Resistance and Combination Therapies: Identifying pathways that become increasingly dysregulated in advanced disease stages or specific cell populations may provide mechanistic insights into treatment resistance. This could inform the development of novel combination therapies designed to simultaneously target multiple critical pathways or overcome resistance mechanisms, thereby improving long-term patient outcomes in lung cancer.

22. Discussion

This comprehensive single-cell analysis provides a multi-faceted view of lung cancer progression, integrating insights into cellular heterogeneity, genomic instability, immune microenvironment remodeling, and cell-cell communication dynamics.

Cellular Heterogeneity and Genomic Instability: UMAP visualizations clearly delineate normal from tumor cells and diploid from aneuploid populations, unequivocally identifying aneuploid Lung Epithelial cells as the malignant population driving tumor growth. A critical finding is the early onset of genomic instability, with significant aneuploidy observed even in 'Tumor(early)' samples (Section 11). CNV analysis of these tumor-origin cells reveals widespread alterations, including recurrent amplifications of key oncogenes such as EGFR and ERBB2, reinforcing their established roles in lung cancer pathogenesis (Section 4). The presence of both aneuploid and diploid Lung Epithelial cells within tumor samples highlights intra-tumoral heterogeneity, which is crucial for understanding clonal evolution and therapeutic resistance.

Immune Microenvironment Remodeling: The immune landscape undergoes profound remodeling from normal to advanced disease. Population analyses show a consistent and statistically significant depletion of natural killer (NK) cells in both early and advanced tumor stages, indicating an early compromise of innate anti-tumor immunity (Section 8). Concurrently, regulatory T cells (Tregs) are significantly expanded in early tumors, contributing to an immunosuppressive milieu. Macrophage populations exhibit a complex repolarization: while the overall M1-like phenotype decreases, there is a striking and highly significant increase in the pro-tumorigenic Mac (M2B) subset in advanced tumors, coupled with a surprising decrease in M2A and M2C subsets (Sections 9, 10). This suggests a specific, dynamic macrophage adaptation in advanced disease, rather than a generic M2-shift. GSEA further highlights widespread immune pathway modulation, including the strong enrichment of 'PD-L1 expression and PD-1 checkpoint pathway' in T cells within tumor conditions, consistent with immune evasion mechanisms (Section 21).

Cell-Cell Communication Dynamics: Intercellular communication networks are fundamentally reprogrammed in the tumor microenvironment. While normal tissues display robust adhesive interactions (e.g., ICAM2_integrin_aLb2_complex), tumor conditions show a reduction in many homeostatic interactions and an emergence of pro-tumorigenic cross-talk (Section 14). Notably, aneuploid Lung Epithelial cells engage in robust autocrine and paracrine EGFR signaling (e.g., AREG-EGFR, HBEGF-EGTR) which intensifies with disease progression (Section 13). Interactions involving TGFB1 with its receptors also become prominent, suggesting active immunosuppression and fibrosis (Section 12, 13). Upregulation of integrins (e.g., ITGAV, ITGB5) and matrix metalloproteinases (e.g., MMP14) in cancer-associated fibroblasts (CAFs) points to active extracellular matrix remodeling supporting tumor invasion (Section 17). The CXCL12_CXCR4 axis between fibroblasts and macrophages also emerges as a key interaction, recruiting immunosuppressive cells (Section 14).

Metabolic and Proliferative Reprogramming: Gene Ontology (GSA) and Gene Set Enrichment Analysis (GSEA) reveal a profound shift in Lung Epithelial cells from immune/metabolic homeostasis in normal tissue to hyperactive protein synthesis and processing ('Ribosome', 'Spliceosome', 'Protein processing in ER') and core cancer pathways ('HIF-1 signaling', 'VEGF signaling', 'MAPK signaling', 'Pathways in cancer') in tumor states (Sections 20, 21). This is further supported by the widespread upregulation of cell cycle genes (e.g., MCMs, CCNB1, CDKs) in tumor epithelial cells (Section 19), reflecting uncontrolled proliferation. The downregulation of GADD45B in advanced tumor epithelial cells suggests a compromised DNA damage response, further contributing to genomic instability. These findings collectively paint a picture of highly adapted malignant cells and a dynamically evolving, supportive, and immunosuppressive microenvironment that orchestrates lung cancer progression from its early stages.

Hypotheses:

  1. Early genomic instability, characterized by aneuploidy and recurrent CNVs (e.g., EGFR, ERBB2 amplification) in Lung Epithelial cells, drives initial malignant transformation, cellular reprogramming, and sets the stage for immune evasion in lung cancer.
  2. The specific polarization of macrophages towards an M2B-like phenotype, coupled with a decrease in M2A/M2C subsets, represents a distinct and critical pro-tumorigenic adaptation in the advanced lung cancer microenvironment that can be targeted for therapeutic benefit.
  3. Aberrant cell-cell communication, particularly through amplified EGFR, TGF-β, and integrin signaling, creates a permissive and immunosuppressive tumor microenvironment that actively supports tumor growth, invasion, and metastasis across disease stages.
  4. The sustained depletion of NK cells and enrichment of Tregs from early lung cancer stages contribute significantly to impaired anti-tumor immunity, allowing for tumor establishment and progression.
  5. Widespread metabolic and proliferative reprogramming, evidenced by the consistent upregulation of cell cycle machinery and pathways related to protein synthesis, drives the rapid expansion of malignant Lung Epithelial cells throughout lung cancer development.

Potential therapeutic targets:

  1. EGFR (Epidermal Growth Factor Receptor): EGFR is a well-established oncogene consistently highly expressed, amplified, and actively signaling in aneuploid Lung Epithelial cells across early and advanced tumor stages. Its signaling drives cell proliferation, survival, and influences the tumor microenvironment. Evidence: CNV analysis (Section 4) shows EGFR amplification in the 7p13:7q11.23 region. Surfaceome marker dot plot (Section 15) demonstrates strong, widespread expression in aneuploid Lung Epithelial cells. Cell-cell interaction analysis (Section 13) reveals robust autocrine and paracrine EGFR signaling (e.g., AREG-EGFR, HBEGF-EGTR, EREG-EGFR, TGFA-EGFR) in these tumor cells, intensifying with progression. GSEA (Section 21) indicates 'MAPK signaling pathway' enrichment, a key downstream effector of EGFR, in Lung Epithelial cells in tumor conditions. Validation: Test the efficacy of EGFR tyrosine kinase inhibitors (e.g., gefitinib, osimertinib) or monoclonal antibodies (e.g., cetuximab) *in vitro* on patient-derived lung cancer cell lines or organoids, and *in vivo* in patient-derived xenograft (PDX) models. Monitor EGFR expression and activation (e.g., phospho-EGFR) via immunohistochemistry/immunofluorescence in tumor biopsies before and after treatment to correlate with response.
  2. FAP (Fibroblast Activation Protein alpha): FAP is a canonical marker of activated Cancer-Associated Fibroblasts (CAFs), significantly and consistently upregulated in early tumor fibroblasts. FAP-expressing CAFs promote ECM remodeling, tumor growth, invasion, angiogenesis, and immune suppression, representing a key stromal target. Evidence: Surfaceome marker dot plot (Section 17) demonstrates FAP as strongly upregulated and highly prevalent in fibroblasts from early tumor samples, with minimal expression in normal fibroblasts. GSEA (Section 21) shows 'TGF-beta signaling pathway' enrichment in Fibroblasts in tumor conditions, a pathway known to drive CAF activation. Validation: Preclinical testing of FAP-targeting agents (e.g., FAP-targeted antibodies, antibody-drug conjugates, or radioligands) *in vitro* on CAF models and *in vivo* in lung cancer mouse models to assess their impact on tumor growth, metastasis, and tumor microenvironment modulation. Use immunohistochemistry/immunofluorescence for FAP expression in patient tumor samples to identify CAF-rich tumors for patient stratification.
  3. TIGIT (T cell immunoreceptor with Ig and ITIM domains): TIGIT is a prominent co-inhibitory receptor highly expressed on exhausted CD4+ T cells in the tumor microenvironment. Its presence contributes to immunosuppression and T cell dysfunction, making it a promising target for immune checkpoint blockade. Evidence: Surfaceome marker dot plot (Section 18) shows TIGIT as notably upregulated in CD4+ T cells from both early and advanced tumor samples compared to normal. GSEA (Section 21) indicates strong enrichment of the 'PD-L1 expression and PD-1 checkpoint pathway in cancer' in T cells in tumor conditions, suggesting a broader landscape of immune checkpoint activation including TIGIT. Validation: Evaluate the efficacy of anti-TIGIT antibodies (alone or in combination with anti-PD-1/PD-L1 therapies) in preclinical lung cancer models to assess their ability to restore T cell function and enhance anti-tumor immunity. Perform flow cytometry on tumor-infiltrating lymphocytes (TILs) from patients to monitor TIGIT expression and its correlation with T cell exhaustion markers and clinical response.
  4. CXCR4 (C-X-C Motif Chemokine Receptor 4) / CXCL12 axis: The CXCL12-CXCR4 axis is a critical chemokine signaling pathway prominently enriched in tumor conditions, mediating the recruitment of tumor-associated macrophages (TAMs) and other immunosuppressive cells into the tumor microenvironment, thereby promoting immunosuppression, angiogenesis, and metastasis. Evidence: Condition-specific cell-cell interaction analysis (Section 14) identifies a significant CXCL12_CXCR4 interaction between Fibroblasts (CXCL12-producing) and Macrophages (CXCR4-expressing) that is enriched in tumor conditions. GSEA (Section 21) shows 'Chemokine signaling pathway' enrichment in macrophages in tumor contexts, aligning with their migratory roles. Validation: Test CXCR4 antagonists (e.g., Plerixafor) *in vitro* to inhibit the migration of tumor-associated immune cells (e.g., macrophages, Tregs) and *in vivo* in mouse models to assess effects on TAM recruitment, T cell infiltration, and tumor growth. Utilize spatial transcriptomics or multiplex immunohistochemistry to confirm CXCL12/CXCR4 expression and colocalization of fibroblasts and macrophages in patient tumor regions.
  5. ERBB2 (HER2 - Human Epidermal Growth Factor Receptor 2): ERBB2 is another receptor tyrosine kinase from the ERBB family, exhibiting amplification and overexpression in aneuploid Lung Epithelial cells from tumor samples. This indicates its activation as a driver of tumor growth and progression, often associated with aggressive disease subtypes. Evidence: CNV analysis (Section 4) explicitly shows ERBB2 amplification in the 17q21.1:17q21.2 region across multiple tumor samples. The surfaceome marker dot plot (Section 15) confirms upregulated expression of ERBB2 in aneuploid Lung Epithelial cells within tumor conditions, with minimal expression in normal cells. Validation: Test HER2-targeted therapies, such as antibody-drug conjugates (e.g., trastuzumab deruxtecan) or small molecule tyrosine kinase inhibitors (e.g., poziotinib), *in vitro* and *in vivo* in lung cancer models harboring ERBB2 alterations. Perform immunohistochemistry or FISH for HER2 expression/amplification in patient biopsies to guide patient selection for HER2-targeted treatments.

Follow-up validation ideas:

  1. Perform FISH or qPCR on microdissected tumor regions or FACS-sorted aneuploid Lung Epithelial cells to validate specific gene amplifications (e.g., EGFR, ERBB2) identified by CNV analysis.
  2. Conduct multiparametric flow cytometry or immunohistochemistry on fresh/FFPE lung tissue biopsies across disease stages to quantify and spatially map changes in T cell (Treg, NK cell), and macrophage (M1, M2A/B/C) subset populations.
  3. Establish co-culture systems of primary lung cancer epithelial cells with fibroblasts or macrophages, using blocking antibodies or genetic knockdowns for identified ligand-receptor pairs (e.g., CXCL12-CXCR4, EGFR ligands) to assess their impact on proliferation, migration, and immune modulation.
  4. Utilize spatial transcriptomics or multiplex immunofluorescence to confirm the colocalization and activity of key interacting cell types (e.g., FAP+ fibroblasts with tumor cells, TIGIT+ T cells with PD-L1+ tumor cells) and their respective surface markers within the tumor microenvironment.
  5. Perform *in vitro* functional assays (e.g., migration, invasion, proliferation assays) with fibroblast cell lines or patient-derived CAFs, perturbing expression of FAP, MMP14, or integrins (e.g., ITGAV/ITGB5) to validate their pro-tumorigenic roles.
  6. Employ CRISPR/Cas9 or siRNA knockdown in lung cancer cell lines to assess the functional impact of highly upregulated cell cycle genes (e.g., MCM4, CDK4) or those in enriched GSEA pathways (e.g., HIF-1, MAPK) on cell proliferation and survival.
  7. Validate the functional consequences of macrophage M2B polarization using *in vitro* assays (e.g., cytokine secretion, phagocytosis, matrix degradation) by culturing macrophages with factors from advanced tumor conditioned media, followed by targeted gene expression analysis.

Limitations:

This report is based on a single-cell RNA-seq dataset, providing a snapshot of the cellular and molecular landscape at various disease stages. The cross-sectional nature limits inferences about dynamic processes and requires longitudinal validation. While the inferred disease context of Lung Cancer is strongly supported by metadata and genomic findings, specific clinical diagnoses or treatment responses are not directly available. Batch effects, though largely mitigated, might subtly influence cross-sample comparisons. The identification of tumor-origin cells relies on ploidy and CNV estimates, which are computational inferences. Furthermore, validation of proposed therapeutic targets and cellular interactions requires rigorous experimental follow-up, as transcriptomic data primarily indicates potential rather than confirmed functional activity.

23. Query List

  1. Show and save UMAPs for condition, sample, major cell type, minor cell type, ploidy_dec, and celltype_subset in two columns.
  2. Show major cell type scores on UMAP and save the result.
  3. Show and save a marker expression dot plot for celltype_subset. SET target_cell = None and var_group_rotation = 45. Leave all other arguments at their default values.
  4. Select Lung Epithelial cells as tumor-origin cells, show a CNV heatmap grouped by sample together with a summary of regions with significantly amplified copy numbers, and save the results.
  5. Show and save UMAPs of CNV patterns colored by major cell type, minor cell type, ploidy results, condition, and sample in two columns.
  6. Show and save a population bar plot of minor cell types.
  7. Show and save a population bar plot of T cell subsets.
  8. Show and save box plots of T cell subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
  9. Show and save a population bar plot of macrophage subsets.
  10. Show and save box plots of macrophage subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
  11. Select Lung Epithelial cells as tumor-origin cells, show their ploidy populations as a bar plot, and save the result.
  12. Show and save cell-cell interaction patterns involving Lung Epithelial cells, Fibroblast, Macrophage, T cell, and other relevant cell types. Select at most 80 cell-cell interactions per group.
  13. Select only genes associated with immune checkpoint and cell cycle pathways, show cell-cell interactions for these genes, and save the result.
  14. Find cell-cell interactions involving major immune and stromal cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60. For each interaction identified under each condition, using the provided dataset context, describe the associated signaling pathways and mechanisms, its potential as a therapeutic target, and relevant therapeutic agents.
  15. Show marker expressions for Lung Epithelial cells as tumor-origin cells in a dot plot, and save the result. Use only surfaceome markers, with at most 60 markers per condition. For the markers identified under each condition, distinguish between established therapeutic targets and less well-characterized markers with potential as therapeutic targets. For each marker, using the provided dataset context, describe the associated signaling pathways and mechanisms, relevant therapeutic agents, and supporting evidence.
  16. Show marker expressions for Macrophage in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information.
  17. Show marker expressions for Fibroblast in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information.
  18. Show marker expressions for T cell CD4+ in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information.
  19. Among cell cycle pathway genes, select those with statistically significant expression differences between conditions in Lung Epithelial cells, show box plots, and save the result. Set max_n_items_to_plot to 24 and choose ncols based on the total number of panels for an overall width-to-height ratio of approximately 2:3.
  20. Show and save Gene Ontology (GSA) analysis results for Lung Epithelial cells as tumor-origin cells as a bar plot.
  21. Show Gene Set Enrichment Analysis results as a dot plot, and save it. Set the color map to RdBu_r, n_pws_to_show to 120, and target_cells to None.
Top